PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-5.69%
Negative revenue growth while 3088.T stands at 5.25%. Joel Greenblatt would look for strategic missteps or cyclical reasons.
-7.03%
Negative gross profit growth while 3088.T is at 7.35%. Joel Greenblatt would examine cost competitiveness or demand decline.
-15.27%
Negative EBIT growth while 3088.T is at 863.68%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-30.94%
Negative operating income growth while 3088.T is at 9.94%. Joel Greenblatt would press for urgent turnaround measures.
-15.78%
Negative net income growth while 3088.T stands at 554.10%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-15.82%
Negative EPS growth while 3088.T is at 2082.54%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-15.82%
Negative diluted EPS growth while 3088.T is at 2082.54%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
-0.00%
Share reduction while 3088.T is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.00%
Reduced diluted shares while 3088.T is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
-100.00%
Both companies cut dividends. Martin Whitman would look for a common factor, such as cyclical downturn or liquidity constraints.
-50.98%
Negative OCF growth while 3088.T is at 152.59%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-113.96%
Negative FCF growth while 3088.T is at 323.98%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
34.87%
10Y revenue/share CAGR above 1.5x 3088.T's 6.17%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
34.87%
5Y revenue/share CAGR above 1.5x 3088.T's 6.17%. David Dodd would look for consistent product or market expansions fueling outperformance.
34.87%
3Y revenue/share CAGR above 1.5x 3088.T's 6.17%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
78.18%
Net income/share CAGR above 1.5x 3088.T's 47.62% over 10 years. David Dodd would confirm if brand, IP, or scale secure this persistent advantage.
78.18%
5Y net income/share CAGR above 1.5x 3088.T's 47.62%. David Dodd would confirm if the firm’s strategy is more effective in generating mid-term profits.
78.18%
3Y net income/share CAGR above 1.5x 3088.T's 47.62%. David Dodd would confirm the company’s short-term strategies outmatch the competitor significantly.
46.81%
Equity/share CAGR of 46.81% while 3088.T is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
46.81%
Equity/share CAGR of 46.81% while 3088.T is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
46.81%
Equity/share CAGR of 46.81% while 3088.T is zero. Bruce Berkowitz sees if minor gains can snowball into a bigger lead soon.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
5.76%
Inventory growth well above 3088.T's 3.89%. Michael Burry suspects overshooting production or weaker sell-through vs. the competitor.
1.70%
Asset growth above 1.5x 3088.T's 0.91%. David Dodd checks if M&A or new capacity expansions are value-accretive vs. competitor's approach.
4.85%
BV/share growth above 1.5x 3088.T's 2.26%. David Dodd confirms if consistent profit retention or fewer write-downs yield faster equity creation.
-12.38%
Both reduce debt yoy. Martin Whitman sees a broader sector shift to safer balance sheets or less growth impetus.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.